• Genmab reported worldwide net trade sales of DARZALEX of USD 4.24 billion in the third quarter of 2026.
• U.S. net trade sales reached USD 2.53 billion; rest-of-world sales totaled USD 1.71 billion.
• Royalty income tied to worldwide DARZALEX net sales reported by Johnson & Johnson under Genmab’s license agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130622PRIMZONEFULLFEED1001277719) on October 13, 2026, and is solely responsible for the information contained therein.